Mark J. Axelrod - Concepedia

Author

Mark J. Axelrod

University of Virginia

Also Known As

Axelrod, Mark, M Axelrod, Mark Axelrod, Mark J. Axelrod, Mark Joseph Axelrod

Publications

534

Citations

H-Index

Concepts

All Affiliations

University of Virginia George Mason University Gilead Sciences (United States)

About

Mark J. Axelrod is an author at University of Virginia specializing in systems biology, tumor biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	59
2	Cell Biology	2	2	59
3	Engineering	1	1	12
4	Health Sciences	1	1	47
5	Molecular Biology	1	1	47

Mark J. Axelrod

Publications

454

Citations

H-Index

Page 1

	Year	Citations
Hemoglobin conformation couples erythrocyte <i>S</i> -nitrosothiol content to O <sub>2</sub> gradients Allan Doctor, Ruth Platt, Mary Lynn Sheram, Proceedings of the National Academy of Sciences	2005	205
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Blood Advances	2017	104
Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms Mark J. Axelrod, Vicki L. Gordon, Mark R. Conaway, Oncotarget Drug TargetMolecular BiologyCombinatorial DrugTumor BiologyDrug Resistance	2013	47
Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma Devin G. Roller, Mark J. Axelrod, Brian J. Capaldo, Molecular Cancer Therapeutics	2012	34
Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions Craig A. Portell, Mark J. Axelrod, L. Kyle Brett, Blood	2014	28
Combination Effects of B Cell Receptor Pathway Inhibitors (Entospletinib, ONO/GS-4059, and Idelalisib) and a BCL-2 Inhibitor in Primary CLL Cells Randall M. Jones, Mark J. Axelrod, Daniel B. Tumas, Blood	2015	13
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma Brian J. Capaldo, Devin G. Roller, Mark J. Axelrod, PLoS ONE Systems AnalysisSignal TransductionEngineeringCell RegulationAdaptive Responses	2015	12
The Combination of Entospletinib and Vincristine Demonstrates Synergistic Activity in a Broad Panel of Hematological Cancer Cell Lines and Anti-Tumor Efficacy in a DLBCL Xenograft Model Mark J. Axelrod, Peter Fowles, Jeff Silverman, Blood	2015	11

Page 1